Stoke Therapeutics, Inc.
zorevunersen
Dravet syndrome
Resolved
7days ago
Catalyst readout · Jun 30, 2026
What's at stake
A key catalyst for zorevunersen (Dravet syndrome) is expected Jun 30, 2026.
Primary source
· SEC 8-K
verified 15h ago
“enrollment of approximately 150 patients into the Phase 3 EMPEROR study expected to complete in June 2026 to support a data readout in mid-2027.”